March 25, 2009 – Lantheus Medical Imaging Inc. today announced that new data for the company’s echocardiography contrast agent DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension and its novel fluorine 18-labeled Positron Emission Tomography (PET) agent for myocardial perfusion imaging, BMS747158, will be presented in two separate poster presentations at the American College of Cardiology 58th Annual Scientific Session on March 29-31, 2009, in Orlando, Florida.
New data on survival in an intensive care unit population undergoing transthoracic echocardiography with and without perflutren containing ultrasound contrast agents will be presented. The retrospective study includes more than 39,000 propensity-matched cases in patients undergoing transthoracic echocardiography with and without contrast agents. The majority of the perflutren cases used DEFINITY, which is the market-leading product in ultrasound echocardiography contrast agents in the U.S. Additionally, Phase I data regarding the human safety, dosimetry, biodistribution, and myocardial perfusion imaging characteristics under rest and stress conditions of Lantheus’ new PET agent BMS747158 will be presented.
“The new DEFINITY data expand on findings published in December 2008 that showed that the use of DEFINITY for enhancing suboptimal resting echocardiography exams was associated with a 26 percent lower risk of mortality when compared with echocardiography performed without a contrast agent. Additionally, the PET agent data further demonstrate Lantheus’ ongoing commitment to developing new agents for the diagnosis and management of cardiovascular disease,” said Don Kiepert, president and CEO, Lantheus Medical Imaging, Inc.
The abstract “Survival in an Intensive Care Unit Population Undergoing Transthoracic Echocardiography With and Without Perflutren Containing Ultrasound Contrast Agents: Results in 39,189 Propensity Matched Cases” will be presented on Sunday, March 29, 2009, 3:30 p.m. - 4:30 p.m. The presenter is Michael L. Main M.D., associate professor of medicine, University of Missouri-Kansas City and director, echocardiography laboratory, Saint Luke’s Mid America Heart Institute, Kansas City, MI.
The second abstract, “Phase 1 Human Safety, Dosimetry, Biodistribution, and Rest/Stress Myocardial Imaging Characteristics of F-18 Labeled BMS747158,” will be presented on Tuesday, March 31, 2009, 9:30 a.m. - 10:30 a.m., by Jamshid Maddahi, M.D., F.A.C.C., professor of molecular and medical pharmacology (nuclear medicine) and medicine (cardiology) at David Geffen School of Medicine at UCLA.
For more information: www.lantheus.com
August 17, 2023 
